for Performance Horses

2 million performance horses will suffer a tendon or ligament injury this year

Current therapeutic solutions take 9-12 months and often are ineffective, necessitating euthanasia  

Athletes, both equine and human, are expensive;
$6B market opportunity

CellDrop is commercializing a first of its kind encapsulated, allogeneic stem cell therapy for faster and more durable healing of superficial digital flexor tendon and suspensory ligament injuries in performance horses.

Implementation in the veterinary market serves as a stepping stone to human translation, where preliminary evidence shows great promise for reversing debilitating orthopedic conditions like Osteoarthritis.


Get to know the people behind Celldrop
Meet the team